Clinical Trial Update: Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating safety and efficacy of durvalumab plus paclitaxel in metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: King Faisal Specialist Hospital & Research Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED